文献速递瓣膜外科先天性心脏病外科

去细胞同种异体移植物用于儿童主动脉瓣置换的前瞻性多中心随访

Paediatric aortic valve replacement using decellularized allografts.
PubMed 文献 · Eur J Cardiothorac Surg · 2020-01-01

该研究前瞻性随访8个欧洲中心106例接受去细胞主动脉同种移植物(DAH)行主动脉瓣置换的儿童,平均随访3.30年。结果显示主要疗效终点平均峰值压差18.1 mmHg、反流评分0.61良好,5年免于死亡/移植/心内膜炎/出血/卒中分别为97.8%/85.0%/100%/100%/100%。作者认为DAH可能为儿童主动脉瓣置换提供有前景的附加选择。

要点

  • DAH在儿童主动脉瓣置换中显示出良好的血流动力学和早期临床结果。
  • 5年免于心内膜炎、出血和卒中均为100%,免于死亡97.8%,免于移植85.0%。
  • DAH的预期不良事件低于冷冻保存同种移植物和Ross患者,与机械瓣相近。

核心结论

  • 尽管DAH儿童患者总数和随访时间仍有限,数据提示DAH可能为儿童主动脉瓣置换提供有前景的附加选择。

研究设计与样本

  • 前瞻性、多中心随访研究,纳入8个欧洲中心所有接受去细胞主动脉同种移植物行主动脉瓣置换的儿童患者。
  • 共106名儿童(77名男孩),平均年龄10.1±4.8岁,DAH直径20.5±3.8 mm。

主要发现

  • 60例(57%)既往接受过外科手术:34例1次、15例2次、11例≥3次。
  • 早期死亡1例(12岁女孩,第四次主动脉瓣手术,体外膜氧合期间脑出血);另1例2岁患者术后2个月死于脓毒症,无感染性心内膜炎证据。
  • 1例需植入起搏器;1例2.5岁女孩因慢性心肌衰竭 despite 完整DAH 成功接受心脏移植。
  • 平均随访3.30±2.45年,主要疗效终点平均峰值压差18.1±20.9 mmHg,反流平均0.61±0.63(0-3级)。
  • 5年免于死亡/移植/心内膜炎/出血/卒中分别为97.8±1.6%/85.0±7.4%/100%/100%/100%。

关键数值与推荐

  • DAH患者计算预期不良事件低于冷冻保存同种移植物患者(平均年龄8.9岁)和Ross患者(9.4岁),与机械主动脉瓣置换患者(12.8岁)范围相同。

临床怎么用

  • 对于无法行瓣膜修复的儿童主动脉瓣置换,DAH可作为除Ross手术和机械瓣之外的附加选择。
  • 需关注术后起搏器植入、慢性心肌衰竭需移植及感染等并发症。

局限性

  • DAH儿童患者总体数量有限,随访时间跨度仍较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Options for paediatric aortic valve replacement (AVR) are limited if valve repair is not feasible. Results of paediatric Ross procedures are inferior to adult Ross results, and mechanical AVR imposes constant anticoagulation with the inherent risks. METHODS: The study design was a prospective, multicentre follow-up of all paediatric patients receiving decellularized aortic homografts (DAHs) for AVR in 8 European centres. RESULTS: A total of 106 children (77 boys) were operated (mean age 10.1 ± 4.8 years, DAH diameter 20.5 ± 3.8 mm). A total of 60 (57%) had undergone previous surgical interventions: 34 with 1, 15 with 2 and 11 with ≥3. There was one early death in a 12-year-old girl, who underwent her fourth aortic valve operation, due to intracerebral haemorrhage on extracorporeal membrane oxygenation after coronary reimplantation problems following 3-sinus reconstruction 1 year earlier. One 2-year-old patient died due to sepsis 2 months postoperatively with no evidence for endocarditis. In addition, a single pacemaker implantation was necessary and a 2.5-year-old girl underwent successful HTx due to chronic myocardial failure despite an intact DAH. After a mean follow-up of 3.30 ± 2.45 years, primary efficacy end points mean peak gradient (18.1 ± 20.9 mmHg) and regurgitation (mean 0.61 ± 0.63, grade 0-3) were very good. Freedom from death/explantation/endocarditis/bleeding/stroke at 5 years was 97.8 ± 1.6/85.0 ± 7.4/100/100/100% respectively. Calculated expected adverse events were lower for DAH compared to cryopreserved homograft patients (mean age 8.9 years), lower than in Ross patients (9.4 years) and in the same range as mechanical AVR (12.8 years). CONCLUSIONS: Even though the overall number of paediatric DAH patients and the follow-up time span are still limited, our data suggest that DAHs may present a promising additional option for paediatric AVR.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Horke A, Bobylev D, Avsar M, et al. Paediatric aortic valve replacement using decellularized allografts. Eur J Cardiothorac Surg. 2020. PMID: 32443152. doi:10.1093/ejcts/ezaa119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。